Viewing Study NCT01187667


Ignite Creation Date: 2025-12-25 @ 12:54 AM
Ignite Modification Date: 2025-12-25 @ 11:09 PM
Study NCT ID: NCT01187667
Status: COMPLETED
Last Update Posted: 2012-08-10
First Post: 2010-08-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluation of Delirium Prevention in Critically Ill Patients
Sponsor: Radboud University Medical Center
Organization:

Study Overview

Official Title: Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium
Status: COMPLETED
Status Verified Date: 2012-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium
Detailed Description: Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on:

\- delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28 days - days on the ventilator - length of stay on the ICU and In-Hospital - 28-day mortality - incidence of unexpected removal of tubes, and effect between different groups of patients. Safety of haloperidol concerning QT-time, extrapyramidal symptoms.

Data are compared with the data of a historical cohort

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: